 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Pharmacist Specialist, Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, CA; Clinical Professor of Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA; Clinical Professor of Medicine, School of Medicine, University of California Davis
Coordinator, Clinical Services, Department of Pharmaceutical Services, University of California Davis Medical Center; Associate Clinical Professor of Pharmacy, School of Pharmacy, University of California San Francisco
Reprints: Dr. Dager, Department of Pharmaceutical Services, University of California Davis Medical Center, 2315 Stockton Blvd., Sacramento, CA 95817-2201, fax 916/703-4031, william.dager{at}ucdmc.ucdavis.edu
BACKGROUND: Data are limited on aminoglycoside pharmacokinetic differences between acute renal failure (ARF) and chronic kidney disease (CKD) or infection survival when maintaining peak and pre-hemodialysis serum concentrations between 7 and 10 and 3.5 and 5 mg/L, respectively.
OBJECTIVE: To report aminoglycoside pharmacokinetic observations in a consecutive series of patients receiving intermittent hemodialysis (IHD), including treatment impact of patient-specific dosing regimens.
METHODS: In this prospective study, all calculated pharmacokinetic parameters used concentrations drawn more than 12 hours after the initial dose and peak concentrations at least 2 hours after the dose. Analysis included pharmacokinetic parameters in stage 5 CKD, ARF, impact of the dialysis prescription, and treatment results of individualized dosing regimens lasting more than 4 days.
RESULTS: Consecutive patients with IHD (N = 167) receiving 216 courses of aminoglycosides were evaluated. The mean ± SD volume of distribution was 0.39 ± 0.15 L/kg ideal body weight, and elimination half-life during dialysis was 4.2 ± 2.3 hours. The elimination half-life off IHD was 30% shorter in ARF (31.9 ± 20.8 h) versus 45.7 ± 24.2 hours in CKD (p < 0.001). Mean extrapolated peak concentrations and pre-IHD levels were 7.7 ± 1.6 and 3.9 ± 1.2 mg/L, respectively. A 91% treatment success rate was observed in 117 individualized treatment courses in 100 patients receiving greater than or equal to 5 days of aminoglycoside therapy.
CONCLUSIONS: A large variability in aminoglycoside pharmacokinetic parameters in IHD exists, with aminoglycoside elimination off IHD significantly faster in ARF. Individualized regimens using serum concentrations drawn in patients requiring treatment (non-synergistic) targeting peak concentrations of 7–10 mg/L and pre-hemodialysis serum concentrations of 3.5–5 mg/L appears successful for eradicating infections.
Key Words: aminoglycosides, hemodialysis, pharmacokinetics
Published Online, December 6, 2005. www.theannals.com, DOI 10.1345/aph.1G064
This article has been cited by other articles:
|
|
 |
|
  N. N. Salama, J. H. Segal, M. D. Churchwell, J. H. Patel, L. Gao, M. Heung, and B. A. Mueller Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients Nephrol. Dial. Transplant., December 10, 2009; (2009) gfp655v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Sowinski, S. J. Magner, A. Lucksiri, M. K. Scott, R. J. Hamburger, and B. A. Mueller Influence of Hemodialysis on Gentamicin Pharmacokinetics, Removal During Hemodialysis, and Recommended Dosing Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 355 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E Dager Aminoglycoside Elimination in Extended Duration Hemodialysis Ann. Pharmacother., April 1, 2006; 40(4): 783 - 784. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
